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The daily multiple insulin injection is the line of treatment for diabetes mellitus. As the oral insulin delivery mimics, the 
physiology of endogenous insulin secreted by pancreas. Recently, the search for suitable carrier to develop oral insulin 
delivery has been intensified. However, the carrier toxicity and very less bioavailability of insulin remains the major 
problem in the development of oral insulin delivery. Preparation of a non-covalent insulin-peptide complex using different 
peptide made of 16 to 20 L-amino acids studied to overcome the problem. The in vitro testing of insulin-peptide complex 
showed significant stability against the proteolytic enzyme. Whereas, in in vivo testing, the presence of 10-41% insulin in 
blood plasma observed after 30 to 60 min oral feeding of insulin-peptide complex. Results indicated that the peptide which 
showed moderate protection against pepsin and minor protection against trypsin and chymotrypsin has an important role in 
enhancing oral insulin bioavailability. However, the peptide which showed higher protection against trypsin and no 
protection against pepsin could not achieve significant oral insulin bioavailability. 
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Around four million people are dying per year due to 
diabetes mellitus and this disease may reach to 642 
million people by 2040
1
. In general, diabetes mellitus 
is classified as Type 1 and Type 2. Type 1 diabetes 
mellitus is caused by an autoimmune destruction of 
insulin beta cells in the pancreas and is controlled by 
parenteral administration of insulin. Whereas, Type 2 
diabetes is characterized by variable degrees of 
insulin resistance, impaired secretion of insulin and 
increased glucose production, and is generally 
controlled by oral antidiabetic agents. However, when 
these oral antidiabetic agents failed to reduce 
glycemia then these patients are also treated with 
insulin. Thus, insulin is the only effective therapeutic 
agent for the treatment of diabetes mellitus, which is 
being administered parenterally. Although from 
efficacy point of view, the subcutaneous 
administration of exogenous insulin is satisfactory 
route. However, this can result in peripheral 
hyperinsulinemia, which has been associated with 
hypertension, development of atherosclerosis, and 
increased insulin resistance in peripheral and muscle 
tissues. Additionally, the burden of daily injections 
can also result in a psychological discomfort, pain, 
high probability of infections, and local deposition of 
insulin leading to local lipodystrophy at the injection 
site
1
. However, the recent development of a small 
needle for insulin subcutaneous injection is almost 
painless, but the prospect of puncturing the skin still 
elicits significant psychological resistance in most of 
the patients. Another disadvantage of insulin 
subcutaneous injection is delayed absorption, which 
results in a relatively broad plasma insulin peak and a 
prolonged duration of action, potentially increasing 
the risk of hypoglycemia
2
. However, if oral route 
proven feasible for insulin delivery, it would greatly 
boost patient compliance for insulin. As when insulin 
given orally, it is directly channeled from the intestine 
to the liver and a high-level of insulin is reached in 
the portal blood, simulating the physiological 
secretion pattern of the pancreas
3
.However, the carrier 
toxicity and very less bioavailability (therapeutic 
efficacy) of insulin are the major problems in oral 
delivery of insulin, which remains unsolved so far
4,5
. 
As insulin a 51 amino acid peptide cannot be orally 
administered because it is degraded by gastro 
intestinal tract (GIT) proteolytic enzymes
6
. Secondly, 
insulin is less absorbed by the intestinal epithelium 
mainly due to the large size and hydrophilicity of the 
molecule. Other routes such as the inhaled insulin, 
nasal, buccal, and transdermal administration of 
insulin have also been explored, but failed to achieve 










absorption area. Therefore, there is a need of new 
approach to overcome the problem of carrier toxicity 
and bioavailability.  
Recently, many novel techniques have been 
developed to optimize the preparation of oral insulin 
delivery carriers. Nano-particles as a carrier for oral 
insulin delivery has been widely studied
5,7-10
. 
Similarly, other types of carrier for oral insulin 





, and polypeptide-based 
polyelectrolyte
14
. The new approach such as 
modification of carrier surface charge is also reported 
to enhance insulin bioavailability
1,15
. However, the 
problem of toxicity associated with the carrier and 
insulin bioavailability remains by and large unsolved 
so far
4
. Thus, the present study proposed the 
development of peptide made of L-amino acids to 
overcome the carrier toxicity problem. As the 
degradation product of the peptide will be L-amino 
acids and it can be used for the protein synthesis. 
Similarly, the development of a non-covalent insulin-
peptide complex that avoids any chemical 
modification of insulin. Thus, this may result in the 
protection of insulin natural bioactive form and 
achieve desired bioavailability. 
 
Materials and Methods 
Preparation of insulin-peptide complex 
The different peptides comprising of 16-20 L-amino 
acids having positive and/or negative charge with 
hydrophobic and aromatic or cyclic character were 
design and prepared as described elsewhere
16
. The 
purity of all the peptide was around 95% and the  
N- terminal and C-terminal was protected with amide 
and acetyl group respectively. All the chemicals used 
were of ACS grade otherwise specified. The non-
covalent insulin-peptide complex was prepared by 
mixing insulin and peptide. Insulin was purchased as 
recombinant human insulin from Sigma-Aldrich 
Chemical Company (St. Louis, MO). In a glass tube 
insulin (15.0 mg) was dissolved in 3.0 mL solution of 
0.01 N HCl pH 2.0. Similarly, 15.0 mg of peptide was 
dissolved in 3.0 mL solution of 0.01 N HCl pH 2.0. 
Thereafter, 1.0 mL solution of insulin was distributed 
in three glass test tubes and to each tube 1.0 mL 
solution of peptide was added and the mixture was 
allowed to stabilize. Then, the 2.0 mL mixture of 
insulin and peptide present in each tube was subjected 
to dry using Thermo Scientific Speed Vac. The dried 
mixture was termed as insulin-peptide complex and 
stored at −20C till further use.  
Verification of complex formation  
The morphological verification of insulin-peptide 
complex was carried out using scanning electron 
microscopy (SEM). The verification of chemical 
groups present in the insulin-peptide complex was 
studied by performing fourier-transform infrared 
spectroscopy (FTIR). The insulin, peptide and insulin-
peptide complex were scanned using Quanta 200  
3D scanning electron microscope and standard 
procedures were used for preparation of samples. 
FTIR of insulin, peptide and insulin-peptide complex 
was obtained using Perkin Elmer FTIR spectrometer 
in the wavenumber range 500-4000 cm
−1
. Standard 
procedures were used for preparation of samples and 
the respective spectrum is given as it is obtained from 
the instrument. 
 
In vitro testing 
The in vitro testing of insulin-peptide complex was 
carried out to verify the protection of insulin after the 
hydrolysis of insulin-peptide complex by the 
proteolytic enzyme. such as pepsin, trypsin, and 
chymotrypsin (Sigma-Aldrich). The following 
procedure was used to carry out in vitro testing: 
Complex preparation -insulin (18.0 mg) was 
dissolved in 18.0 mL solution of 0.01 N HCl pH 2.0. 
Similarly, 18.0 mg of peptide was dissolved in  
18.0 mL solution of 0.01 N HCl pH 2.0. Thereafter,  
1.0 mL solution of insulin was distributed in eighteen 
glass test tubes and to each tube 1.0 mL solution of 
peptide was added and the mixture was allowed to 
stabilize. Then, the 2.0 mL mixture of insulin and 
peptide present in each tube was subjected to dry 
using Thermo Scientific Speed Vac. The dried 
mixture was termed as insulin-peptide complex and 
stored at −20C till further use. 
Enzyme preparation - pepsin (10.0 mg) was 
dissolved in 20.0 mL solution of 0.01 N HCl pH 2.0 
and trypsin, chymotrypsin 10.0 mg each was 
dissolved in 20.0 mL solution of PBS pH 7.4. Each 
enzyme solution was divided in to two test tubes as 
10.0 mL in each test tube. One test tube carrying 10.0 
mL enzyme solution was termed as active enzyme. 
Another testtube carrying 10.0 mL enzyme solution 
was kept in a boiling water bath for 5 minutes to 
inactivate the enzyme and termed as inactivated 
enzyme.  
Reaction mixture for enzyme hydrolysis:1. 
Reaction mixture for pepsin -Pepsin test (The dried 
insulin-peptide complex + 1.5 mL 0.01 N HCl pH  
2.0 + 0.5 mL active pepsin); Pepsin control (The dried 




insulin-peptide complex + 1.5 mL0.01 N HCl pH  
2.0 + 0.5 mL inactivated pepsin). 2. Reaction mixture 
for trypsin -Trypsin test (The dried insulin-peptide 
complex + 1.5 mL solution of PBS pH 7.4. + 0.5 mL 
active trypsin); Trypsin control (The dried insulin-
peptide complex + 1.5 mL solution of PBS pH 7.4. + 
0.5 mL inactivated trypsin); 3. Reaction mixture for 
chymotrypsin -Chymotrypsin test (The dried insulin-
peptide complex + 1.5 mL solution of PBS pH 7.4. + 
0.5 mL active chymotrypsin); Chymotrypsin control 
(The dried insulin-peptide complex + 1.5 mL solution 
of PBS pH 7.4. + 0.5 mL inactivated chymotrypsin). 
All the reaction mixture for each enzyme was 
prepared in triplicate. The hydrolysis was carried out 
by incubating reaction mixture in a water bath at 37C 
for one hour. After one hour the sample was removed, 
and the verification of insulin protection after the 
hydrolysis of insulin-peptide complex by the 
proteolytic enzyme was carried out using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). The SDS-PAGE was carried out as per 
the procedure described by Laemmli
17
, using a 15.0% 
stacking gel and 4.0% resolving gel and gels were 
stained by Coomassie brilliant blue G-250 (Sigma-
Aldrich). The concentration of insulin in the sample 
loaded on the SDS-PAGE was 12.0 µg before 
hydrolysis. Thus, 12.0 µg insulin was loaded on the 
SDS-PAGE as a control for comparison.  
 
Complex preparation for in vivo testing 
Complex preparation for single peptide: The non-
covalent insulin-peptide complex for single peptide 
such as peptide A, peptide B, peptide C, and peptide 
D was prepared by mixing insulin and peptide. In a 
glass test tube insulin (25.0 mg) was dissolved in  
5.0 mL solution of 0.01 N HCl pH 2.0. Similarly,  
25.0 mg of respective peptide was dissolved in  
5.0 mL solution of 0.01 N HCl pH 2.0. Thereafter,  
1.0 mL solution of insulin was distributed in five 
glass test tube and then 1.0 mL solution of peptide 
was added to each glass test tube and the mixture was 
allowed to stabilize. Then, the 2.0 mL mixture of 
insulin and peptide present in each tube was subjected 
to dry using Thermo Scientific Speed Vac. The dried 
mixture was termed as insulin-peptide complex and 
stored at −20C till further use. 
Complex preparation for double peptide: The non-
covalent insulin-peptide complex fordouble peptide 
such as peptide A+ peptide B (PAPB) and peptide C+ 
peptide D (PCPD) was prepared by mixing insulin 
and peptide. In a glass tube insulin (25.0 mg) was 
dissolved in 5.0 mL solution of 0.01 N HCl pH 2.0. 
Similarly, 12.5 mg of peptide A /peptide C and  
12.5 mg of peptide B / peptide D was dissolved in  
5.0 mL solution of 0.01 N HCl pH 2.0. Thereafter,  
1.0 mL solution of insulin was distributed in five 
glass test tube and then 1.0 mL solution of peptide 
was added to each glass test tube and the mixture was 
allowed to stabilize. Then, the 2.0 mL mixture of 
insulin and peptide present in each tube was subjected 
to dry using Thermo Scientific Speed Vac. The dried 
mixture was termed as insulin-peptide complex and 
stored at −20C till further use. 
 
In vivo testing 
The in vivo testing was carried out at National 
Laboratory Animal Center, CSIR-CDRI, Lucknow, 
India to verify the presence of bioactive insulin in 
blood plasma after feeding the insulin-peptide 
complex through gastro intestinal tract. The dried 
mixture of insulin-peptide complexwas reconstituted 
in pH 2.5 solution and administered orally using 
curved metal gavage needles. Male Sprague Dawley 
rats (200±20 g) available at the National Laboratory 
Animal Center, CSIR-CDRI, Lucknow, India were 
used for the study. The work was conducted in 
accordance with the approval of Institutional Animal 
Ethics Committee (IAEC). The animals were housed 
in polypropylene cages in the animal house, with 
temperature 23±2C, relative humidity 60-70%, 12 h 
day-night cycle, provided standard pellet diet and 
drinking water. At the day of experiment animals 
were fasted (ad libitum) for 6 h. After fasting, blood 
was collected to get the basal (0 min) insulin level 
from all the animals (n=27). The reconstituted 
Insulin-Peptide complex was administered orally  
(5 mg/kg) to animals (n=3 each) and blood from tail 
tip at 30 and 60 min of post-treatment was collected. 
Control group was treated with recombinant human 
insulin (5 mg/kg; n=3) purchased from Sigma-Aldrich 
Chemical Company (St. Louis, MO). The blood was 
centrifuged at 5000 rpm for 5 min at cold and the 
plasma was collected for the measurement of insulin 
using ELISA kit. Level at basal was considered 100% 
and calculation was made to check the availability 
after treatment. 
 
Results and Discussion 
Peptide design 
Many efforts have been going on to develop a 
suitable carrier for oral insulin delivery
1,5,7-15
. 
However, carrier toxicity and low bioavailability 




remains unsolved problem in oral insulin delivery so 
far
4
. Particularly, the problem of carrier toxicity 
becomes more evident in case of diabetes mellitus, as 
it requires lifelong multi-dose treatment to control it. 
In such a case, the prediction of long-term effect of 
carrier toxicity becomes difficult. Thus, the carrier has 
to be as close as to the natural compound that human 
body is used to. This has prompted to use peptide 
made of L-amino acids as a carrier for oral insulin 
delivery. In our previous work, it was found that the 
peptide can significantly protect degradation of 
antisense oligdeoxynucleotides from the nuclease
18
. 
However, not much work is reported regarding the 
use of peptide in the protection of insulin from 
proteolytic enzymes. As the protection of insulin from 
degradation by the proteolytic enzymes is the basic 
criteria in the development of carrier suitable for oral 
insulin delivery. However, some peptide related work 
has been reported in the development of oral  
insulin delivery. The use of polypeptide-based 
polyelectrolyte complexeshas been reported for oral 
insulin delivery, but the raw material showed  
some toxicity
14
.In another report, ~17% relative 
bioavailability was observed when glycyl-glycine and 
alanyl-alanine used to prepare conjugate nanoparticles 
of trimethyl chitosan for oral insulin delivery
9
. Thus, 
in the present study, the strategy to protect insulin 
from proteolytic enzyme and pH shift of stomach and 
intestine was adapted in designing peptide. As the 
insulin molecule has amino acids carrying positive, 
negative charge and hydrophobic character. Secondly, 
the isoelectric point of insulin is around pH 5.3, this 
means the overall charge on insulin molecule may be 
positive in stomach and negative in the intestine. 
Thus, the peptide having negative and/or positive 
charge and hydrophobic character may form the non-
covalent bonding with insulin molecule. This may 
protect insulin from pH shift and proteolytic enzyme 
by shielding the site of action available on the insulin 
molecule. Considering all these factors, the different 
peptide was designed and used to verify their role in 
the protection of insulin from proteolytic enzyme. 
 
In vitro testing 
The in vitro testing was carried out to verify the 
protection of insulin after the hydrolysis of insulin-
peptide complex by the proteolytic enzyme such as 
pepsin, trypsin, and chymotrypsin. The proteolytic 
enzyme such as pepsin, trypsin, and chymotrypsin 
were selected for the testing because these enzymes 
are the principal proteases in the human digestive 
system. Figure 1 shows the band obtained for 
different proteolytic enzyme (test) and insulin as a 
control. The less or more degree of protection 
 
 
Fig. 1 — SDS-PAGE of insulin-peptide complex treated with proteolytic enzyme. [1- Insulin-peptide A complex treated with Pepsin;  
2 - Insulin-peptide B complex treated with Pepsin; 3 - Insulin-peptide B complex treated with Trypsin; 4 - Insulin-peptide B complex 
treated with Chymotrypsin; 5 - Insulin-peptide C complex treated with Trypsin; 6: Insulin-peptide C complex treated with Chymotrypsin; 
7 - Insulin-peptide D complex treated with Pepsin; 8 - Insulin-peptide D complex treated with Trypsin; 9 - Insulin-peptide D complex 
treated with Chymotrypsin; 10 – Insulin (12.5 µg)] 




obtained against respective proteolytic enzyme can be 
seen and understood by comparing the intensity of the 
respective band (1-9) with band number 10 obtained 
for insulin. Insulin-peptide complex made of four 
peptides such as peptide A (Theoretical pI/Mw: 10.70 
/2297.83 Da); peptide B (Theoretical pI/Mw: 10.70/ 
2137.73Da); peptide C (Theoretical pI/Mw: 3.46/ 
2143.38 Da) and peptide D (Theoretical pI/Mw: 4.71/ 
2303.48Da) showed protection against one or more 
proteolytic enzyme. Comparatively, ~10% with 
peptide A against pepsin; ~40%, ~5%, ~2% with 
peptide B against pepsin, trypsin and chymotrypsin 
respectively; ~100% and ~10% with peptide C against 
trypsin and chymotrypsin, respectively; ~2%, ~5%, 
~3% with peptide D against pepsin, trypsin and 
chymotrypsin respectively. Peptide A showed some 
resistance against pepsin, but no resistance against 
trypsin and chymotrypsin. All the control band 
lookalike as band number 5, which was observed for 
insulin-peptide C complex treated with trypsin. 
At pH 2.0 peptide A and insulin has an overall 
positive charged. Thus, interaction between 
hydrophobic amino acid of peptide A and insulin 
might have given some degree of protection from 
pepsin, but not against trypsin and chymotrypsin. As 
pepsin cleavespeptide bonds between aromatic amino 
acids whereas, chymotrypsin cleaves aromatic amino 
acids. Trypsin cleaves peptide chains mainly at the 
carboxyl side of the amino acidslysine or arginine, 
except when either is followed by proline. However, 
peptide B showed comparatively moderate protection 
against pepsin and minor protection against trypsin 
and chymotrypsin. Peptide B has comparatively less 
positive charge than peptide A and it contains proline 
that can cause a kink. Higher protection against 
trypsin and moderate protection against chymotrypsin 
was obtained with peptide C. As at pH 7.4 peptide C 
and insulin has overall negative charge. This might 
have protected carboxyl side of lysine or arginine 
effectively, but moderately protected aromatic amino 
acids. However, peptide D has showed marginal 
protection againstpepsin, trypsin and chymotrypsin. 
Peptide D has overall negative charge and it contains 
proline that might have given some degree of 
protection. However, it was reported that the 
negatively charged insulin was most strongly attracted 
to a negatively charged interface than positively 
charged
19
. Thus, it appears that the net charge of 
insulin may play a secondary role in the interaction 
with a charged surface. Thus, it is difficult to give 
clear explanation as to why some peptide protected 
insulin and some failed. However, the strategy 
adapted in designing the peptide appears to be a 
successful. As the results clearly showed the 
protection of insulin-peptide complex from total 
degradation by proteolytic enzymeat 37C for one h. 
Thus, the peptide A, peptide B, peptide C and peptide 
D selected to carry out in vivo testing. 
 
Verification of complex formation  
The verification of insulin-peptide complex was 
carried out using SEM and FTIR. The pattern 
obtained for all the insulin-peptide complex was 
almost similar. Figure 2 shows themorphology of 
insulin, peptide and insulin-peptide complex obtained 
on SEM. Figure 2 clearly shows the morphology of 
insulin, peptide and insulin-peptide complex is totally 
different. However, the morphology of insulin-peptide 
complex appears well-organized as compare to insulin 
and peptide. This suggests the reorganization of 
insulin and peptide molecules after the complex 
formation. This indicates the formation of non-
covalent linkages between insulin and peptide that 
results in the formation of well-organized structure. 
Figure 3 shows the chemical groups present in the 
insulin, peptide and insulin-peptide complex analyzed 
by the FTIR. The chemical groups present in the form 
of peaks related to insulin and peptide are almost 
present in the insulin-peptide complex. These all the 
observation strongly suggest the formation of a stable 
non-covalent insulin-peptide complex. 
 
In vivo testing 
The four peptides, which showed some positive 
results against proteolytic enzyme (3.2) were selected 
to carry out in vivo testing. Figure 4 shows the 
availability of bioactive insulin in blood plasma  
after feeding insulin-peptide complex through GIT.  
In comparison with control (0 min: 100 ± 
8.53%),peptide B (30 min: 117.37 ± 13.10%; 60 min: 
130.61 ± 0.48%), peptide C (30 min: 110.48 ± 
8.71%), peptide PAPB (30 min: 141.22 ± 21.41%) 
and peptide PCPD (30 min: 116.70 ± 1.48%) showed 
increase in plasma insulin level after the GIT 
administration. After 60 min of GIT administration of 
insulin-peptide B complex, almost 30% stable 
increase in plasma insulin level was obtained. This 
appears to be a significant improvement in an oral 
insulin bioavailability. On the contrary, 5.2% relative 
pharmacological availability of the insulin was 
observed after oral insulin delivery via surface 
hydrophilic modification of chitosan copolymer based  
 











Fig. 3 — Fourier-transform infrared spectroscopy spectra of (A) insulin; (B) Peptide and (C) Insulin-peptide complex. Figures are given 
as it is obtained from the instrument without any modification 






Fig. 4 — Availability of insulin in blood plasma after feeding insulin-peptide complex through gastro intestinal tract. [PA- Insulin-peptide 
A complex; PB - Insulin-peptide B complex; PC - Insulin-peptide C complex; PD- Insulin-peptide D complex; PAPB - Insulin-peptide  





nanoparticles made of poly (d, lactic-co-glycolic) acid 
showed less than 20% insulin bioavailability
15
. 
Whereas, 15.9% insulin oral bioavailability  
was reported with deoxycholic acid-modified 
nanoparticles
20
. The oral administration of glycyl-
glycine and alanyl-alanine conjugate nanoparticles of 
trimethyl chitosan demonstrated 17.19% and 15.46% 
relative insulin bioavailability increase respectively
9
. 
In summary, the strategy adapted showed almost 40% 
oral insulin bioavailability. On the contrary, 
approximately 50% bioavailability was reported when 






The results clearly showed that the strategy used in 
the present study has a high potential to achieve oral 
insulin bioavailability comparable with subcutaneous 
injection
21
, or perhaps better. As the 130.61 ± 0.48% 
and 141.22 ± 21.41% oral insulin bioavailability was 
obtained with peptide B and peptide A+B 
respectively. This appears that the peptide which 
showed moderate protection against pepsin and minor 
protection against trypsin and chymotrypsin has an 
important role in enhancing oral insulin 
bioavailability. Comparatively, the peptide which 
showed higher protection against trypsin and no 
protection against pepsin could not achieve significant 
oral insulin bioavailability. The further study such as 
optimization of peptide concentration and peptide 
combination in the formation of insulin-peptide 
complex will certainly evolve a safe, effective and 
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